The synthetic β-nitrostyrene derivative CYT-Rx20 induces breast cancer cell death and autophagy via ROS-mediated MEK/ERK pathway

Cancer Letters

Volumn 371, Issue 2, 2016, Pages 251-261

  Hung, Amos C ^a   Tsai, Chun Hao ^a,b   Hou, Ming Feng ^a   Chang, Wen Lin ^a   Wang, Chie Hong ^a   Lee, Yi Chen ^a,c   Ko, Alice ^d   Hu, Stephen Chu Sung ^a,b   Chang, Fang Rong ^e   Hsieh, Pei Wen ^f   Yuan, Shyng Shiou F ^a,b  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d UNIVERSITY OF WESTERN ONTARIO   (Canada)

^e KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^f CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Breast cancer; MEK ERK; Reactive oxygen species; Nitrostyrene

Indexed keywords

AUTOPHAGY PROTEIN 5; BAFILOMYCIN A1; BECLIN 1; CASPASE; CHLOROQUINE; CYT RX 20; GLUTATHIONE; HISTONE H2AX; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; REACTIVE OXYGEN METABOLITE; STYRENE DERIVATIVE; UNCLASSIFIED DRUG; 3-HYDROXY-4-METHOXY-BETA-METHYL-BETA-NITROSTYRENE; ANTINEOPLASTIC AGENT; ANTIOXIDANT; APOPTOSIS REGULATORY PROTEIN; ATG5 PROTEIN, HUMAN; BECN1 PROTEIN, HUMAN; H2AFX PROTEIN, HUMAN; HISTONE; LIGHT CHAIN 3, HUMAN; MEMBRANE PROTEIN; MICROTUBULE ASSOCIATED PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHAGY; BREAST CANCER; BREAST CANCER CELL LINE; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME REGULATION; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; BREAST NEOPLASMS; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; MCF 7 CELL LINE; METABOLISM; NUDE MOUSE; OXIDATIVE STRESS; PHOSPHORYLATION; SIGNAL TRANSDUCTION; ULTRASTRUCTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; APOPTOSIS REGULATORY PROTEINS; AUTOPHAGY; BREAST NEOPLASMS; CASPASES; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; G2 PHASE CELL CYCLE CHECKPOINTS; HISTONES; HUMANS; MCF-7 CELLS; MEMBRANE PROTEINS; MICE, INBRED BALB C; MICE, NUDE; MICROTUBULE-ASSOCIATED PROTEINS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; OXIDATIVE STRESS; PHOSPHORYLATION; POLY(ADP-RIBOSE) POLYMERASES; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; STYRENES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84963636042     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.11.035     Document Type: Article

References (49)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J. Clin 2010, 60:277-300.
2. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2015. CA Cancer J. Clin 2015, 65:5-29.
3. Perou C.M., Sorlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
4. Foulkes W.D., Smith I.E., Reis-Filho J.S. Triple-negative breast cancer. N. Engl. J. Med 2010, 363:1938-1948.
5. Zhang J., Wang Z., Hu X., Wang B., Wang L., Yang W., et al. Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer. Int. J. Cancer 2015, 136:204-211.
6. Kolacinska A., Chalubinska J., Zawlik I., Szymanska B., Borowska-Garganisz E., Nowik M., et al. Apoptosis-, proliferation, immune function-, and drug resistance-related genes in ER positive, HER2 positive and triple negative breast cancer. Neoplasma 2012, 59:424-432.
7. Billard W., Peets E. Sulfhydryl reactivity: mechanism of action of several antiviral compounds - selenocystine, 4-(2-propinyloxy)-beta-nitrostyrene, and acetylaranotin. Antimicrob. Agents Chemother 1974, 5:19-24.
8. Chen I.H., Chang F.R., Wu Y.C., Kung P.H., Wu C.C. 3,4-Methylenedioxy-beta-nitrostyrene inhibits adhesion and migration of human triple-negative breast cancer cells by suppressing beta1 integrin function and surface protein disulfide isomerase. Biochimie 2015, 110:81-92.
9. Hamdellou L., Hernandez O., Meinnel J. 4-Dimethylamino-beta-nitrostyrene and 4-dimethylamino-beta-ethyl-beta-nitrostyrene at 100 K. Acta Crystallogr. C 2006, 62:o557-o560.
10. Calgarotto A.K., da Silva Pereira G.J., Bechara A., Paredes-Gamero E.J., Barbosa C.M., Hirata H., et al. Autophagy inhibited Ehrlich ascitic tumor cells apoptosis induced by the nitrostyrene derivative compounds: relationship with cytosolic calcium mobilization. Eur. J. Pharmacol 2012, 678:6-14.
11. Park J., Pei D. trans-Beta-nitrostyrene derivatives as slow-binding inhibitors of protein tyrosine phosphatases. Biochemistry 2004, 43:15014-15021.
12. Carter K.C., Finnon Y.S., Daeid N.N., Robson D.C., Waddell R. The effect of nitrostyrene on cell proliferation and macrophage immune responses. Immunopharmacol. Immunotoxicol 2002, 24:187-197.
13. Rahmani-Nezhad S., Safavi M., Pordeli M., Ardestani S.K., Khosravani L., Pourshojaei Y., et al. Synthesis, in vitro cytotoxicity and apoptosis inducing study of 2-aryl-3-nitro-2H-chromene derivatives as potent anti-breast cancer agents. Eur. J. Med. Chem 2014, 86:562-569.
14. Zeng Z., Sun Z., Huang M., Zhang W., Liu J., Chen L., et al. Nitrostyrene derivatives act as RXRalpha ligands to inhibit TNFalpha activation of NF-kappaB. Cancer Res 2015, 75:2049-2060.
15. Hsieh P.W., Chang Y.T., Chuang W.Y., Shih H.C., Chiang S.Z., Wu C.C. The synthesis and biologic evaluation of anti-platelet and cytotoxic beta-nitrostyrenes. Bioorg. Med. Chem 2010, 18:7621-7627.
16. Wang W.Y., Hsieh P.W., Wu Y.C., Wu C.C. Synthesis and pharmacological evaluation of novel beta-nitrostyrene derivatives as tyrosine kinase inhibitors with potent antiplatelet activity. Biochem. Pharmacol 2007, 74:601-611.
17. Chen Y.J., Chen H.P., Cheng Y.J., Lin Y.H., Liu K.W., Chen Y.J., et al. The synthetic flavonoid WYC02-9 inhibits colorectal cancer cell growth through ROS-mediated activation of MAPK14 pathway. Life Sci 2013, 92:1081-1092.
18. Chen Y.J., Cheng Y.J., Hung A.C., Wu Y.C., Hou M.F., Tyan Y.C., et al. The synthetic flavonoid WYC02-9 inhibits cervical cancer cell migration/invasion and angiogenesis via MAPK14 signaling. Gynecol. Oncol 2013, 131:734-743.
19. Paglin S., Hollister T., Delohery T., Hackett N., McMahill M., Sphicas E., et al. A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles. Cancer Res 2001, 61:439-444.
20. Kuo P.L., Hsu Y.L., Cho C.Y. Plumbagin induces G2-M arrest and autophagy by inhibiting the AKT/mammalian target of rapamycin pathway in breast cancer cells. Mol. Cancer Ther 2006, 5:3209-3221.
21. Stoyianni A., Goussia A., Pentheroudakis G., Siozopoulou V., Ioachim E., Krikelis D., et al. Immunohistochemical study of the epithelial-mesenchymal transition phenotype in cancer of unknown primary: incidence, correlations and prognostic utility. Anticancer Res 2012, 32:1273-1281.
22. Ciaccio M.F., Wagner J.P., Chuu C.P., Lauffenburger D.A., Jones R.B. Systems analysis of EGF receptor signaling dynamics with microwestern arrays. Nat. Methods 2010, 7:148-155.
23. Subik K., Lee J.F., Baxter L., Strzepek T., Costello D., Crowley P., et al. The expression patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by immunohistochemical analysis in breast cancer cell lines. Breast Cancer (Auckl) 2010, 4:35-41.
24. Bellot G.L., Liu D., Pervaiz S. ROS, autophagy, mitochondria and cancer: ras, the hidden master?. Mitochondrion 2013, 13:155-162.
25. Li Z.Y., Yang Y., Ming M., Liu B. Mitochondrial ROS generation for regulation of autophagic pathways in cancer. Biochem. Biophys. Res. Commun 2011, 414:5-8.
26. Dewaele M., Maes H., Agostinis P. ROS-mediated mechanisms of autophagy stimulation and their relevance in cancer therapy. Autophagy 2010, 6:838-854.
27. Lockshin R.A., Zakeri Z. Apoptosis, autophagy, and more. Int. J. Biochem. Cell Biol 2004, 36:2405-2419.
28. Seglen P.O., Gordon P.B. 3-Methyladenine: specific inhibitor of autophagic/lysosomal protein degradation in isolated rat hepatocytes. Proc. Natl. Acad. Sci. U.S.A. 1982, 79:1889-1892.
29. Puissant A., Fenouille N., Auberger P. When autophagy meets cancer through p62/SQSTM1. Am. J. Cancer Res 2012, 2:397-413.
30. Ni H.M., Bockus A., Wozniak A.L., Jones K., Weinman S., Yin X.M., et al. Dissecting the dynamic turnover of GFP-LC3 in the autolysosome. Autophagy 2011, 7:188-204.
31. Hsieh C.H., Pai P.Y., Hsueh H.W., Yuan S.S., Hsieh Y.C. Complete induction of autophagy is essential for cardioprotection in sepsis. Ann. Surg 2011, 253:1190-1200.
32. Lin C.W., Lo S., Perng D.S., Wu D.B., Lee P.H., Chang Y.F., et al. Complete activation of autophagic process attenuates liver injury and improves survival in septic mice. Shock 2014, 41:241-249.
33. Yamamoto A., Tagawa Y., Yoshimori T., Moriyama Y., Masaki R., Tashiro Y. Bafilomycin A1 prevents maturation of autophagic vacuoles by inhibiting fusion between autophagosomes and lysosomes in rat hepatoma cell line, H-4-II-E cells. Cell Struct. Funct 1998, 23:33-42.
34. Milhazes N., Calheiros R., Marques M.P., Garrido J., Cordeiro M.N., Rodrigues C., et al. Beta-nitrostyrene derivatives as potential antibacterial agents: a structure-property-activity relationship study. Bioorg. Med. Chem 2006, 14:4078-4088.
35. Janicke R.U., Sprengart M.L., Wati M.R., Porter A.G. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J. Biol. Chem 1998, 273:9357-9360.
36. Yang Z.J., Chee C.E., Huang S., Sinicrope F.A. The role of autophagy in cancer: therapeutic implications. Mol. Cancer Ther 2011, 10:1533-1541.
37. Ellington A.A., Berhow M.A., Singletary K.W. Inhibition of Akt signaling and enhanced ERK1/2 activity are involved in induction of macroautophagy by triterpenoid B-group soyasaponins in colon cancer cells. Carcinogenesis 2006, 27:298-306.
38. Wang J., Whiteman M.W., Lian H., Wang G., Singh A., Huang D., et al. A non-canonical MEK/ERK signaling pathway regulates autophagy via regulating Beclin 1. J. Biol. Chem 2009, 284:21412-21424.
39. Roy B., Pattanaik A.K., Das J., Bhutia S.K., Behera B., Singh P., et al. Role of PI3K/Akt/mTOR and MEK/ERK pathway in Concanavalin A induced autophagy in HeLa cells. Chem. Biol. Interact 2014, 210:96-102.
40. Zeng Y., Yang X., Wang J., Fan J., Kong Q., Yu X. Aristolochic acid I induced autophagy extenuates cell apoptosis via ERK 1/2 pathway in renal tubular epithelial cells. PLoS ONE 2012, 7:e30312.
41. Manov I., Pollak Y., Broneshter R., Iancu T.C. Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib - the role of extracellular signal-regulated kinase counteraction. FEBS J. 2011, 278:3494-3507.
42. Gallo K.A., Johnson G.L. Mixed-lineage kinase control of JNK and p38 MAPK pathways. Nat. Rev. Mol. Cell Biol 2002, 3:663-672.
43. Sridharan S., Jain K., Basu A. Regulation of autophagy by kinases. Cancers 2011, 3:2630-2654.
44. Delaunay-Moisan A., Appenzeller-Herzog C. The antioxidant machinery of the endoplasmic reticulum: protection and signaling. Free Radic. Biol. Med 2015, 83:341-351.
45. Cheng Z., Ristow M. Mitochondria and metabolic homeostasis. Antioxid. Redox Signal 2013, 19:240-242.
46. Palmer H.J., Paulson K.E. Reactive oxygen species and antioxidants in signal transduction and gene expression. Nutr. Rev 1997, 55:353-361.
47. Landry W.D., Cotter T.G. ROS signalling, NADPH oxidases and cancer. Biochem. Soc. Trans 2014, 42:934-938.
48. 2+-ERK pathways in HepG2 cells. Cell Biochem. Biophys 2013, 67:1433-1439.
49. Rushworth G.F., Megson I.L. Existing and potential therapeutic uses for N-acetylcysteine: the need for conversion to intracellular glutathione for antioxidant benefits. Pharmacol. Ther 2014, 141:150-159.